CLRB•benzinga•
Cellectar Biosciences Received A Letter From Nasdaq Informing The Company That It Had Regained Compliance With Nasdaq Listing Rule 5250(c)(1)
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga